A futility trial of sirolimus in multiple system atrophy

Brief description of study

The purpose of this research is to determine if sirolimus is able to slow the progression of disease in people with multiple system atrophy (MSA). Sirolimus is an immunosuppressant drug that is approved by the U.S. Food and Drug Administration (FDA) to prevent organ transplant rejection and for the treatment of lymphangioleiomiomatosis, a rare progressive lung disease. In this study, the use of sirolimus is considered investigational because it is not FDA approved for slowing the progression of MSA.

Clinical Study Identifier: s17-01392
ClinicalTrials.gov Identifier: NCT03589976
Principal Investigator: Jose Alberto Palma Carazo
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.